Sabinsa snaps up five US patents for probiotics, sports nutrition and male sexual dysfunction
04 Jan 2021 --- The Semi-Sabinsa Group has strengthened its intellectual property protection with five new US patents. They detail new applications for flagship probiotic LactoSpore, as well as covering novel compositions, including for sports nutrition and men’s health.
“Patenting our discoveries is an important part of protecting the investments our customers make when they formulate with our ingredients,” comments Dr. Muhammed Majeed, Sabinsa’s founder and chairperson.
A combination of Lactospore and the company’s beta-glucogallin product Saberry has been patented for inhibiting the growth of Helicobacter pylori, which can cause extra-gastroduodenal disorders.
The composition can be taken in various forms, including tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables or candies.
LactoSpore has also been granted a patent for its potential in reducing intestinal gas (flatulence) formed by the fermentation of food by microbes. According to the patent, culturing LactoSpore and prebiotic fibers along with gas-producing microbes cuts the amount of gas created.
The patent also claims a method for inhibiting the growth of gas-producing microbes such as Escherichia coli, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter johnsonii, Methanobrevibacter smithii, Bilophila wadsworthia and Clostridium difficile.
Boswellia for sports performance
In the sports nutrition category, Sabinsa was granted a patent for its endurance composition. It features boswellic acids, which are polysaccharides derived from Boswellia serrata and branded by the company as Boswellin PS.
This is combined with either the concentrate of the liquid endosperm of Cocos nucifera or the extract of Emblica officinalis fruit standardized to contain at least 10 percent w/w of 1-O-galloyl-β-D-glucose (β-glucogallin).
The patented adaptogenic composition is touted as increasing the endurance capacity under sustained physical activity. The composition also protects against hypoxic injury, modifies biochemical parameters and increases neuromuscular coordination in subjects exposed to amplified physical stress.
These five US patents join a long list of international patents recently gained by Sabinsa.
Addressing male sexual dysfunction
Another patent covers Sabinsa’s composition for managing male sexual dysfunction. The composition consists of Withania somnifera, Mucuna pruriens, Coleus forskohlii and Kaempferia parviflora extracts, all standardized to contain specific active ingredients. These are combined with bioavailability enhancer BioPerine.
The composition modifies different biochemical markers and pathways. This allows it to reduce multiple conditions of male sexual dysfunction, including reduced libido, erectile dysfunction, premature ejaculation and delayed or inhibited ejaculation.
Patents abound
Finally, a fifth patent has been issued for Sabinsa’s composition for inhibiting the prostaglandin transporter (PGT), a transmembrane protein involved in the transport of prostaglandins into the cell.
According to the company, PGT is increasingly becoming a target for the development of drugs to curtail the harmful effects brought about by the uptake of PGs into the cells. This may lead to clinical conditions like hypertension and cardiovascular complications.
Sabinsa’s composition of extracts of Allium sativum, Beta vulgaris, Nigella sativa and Terminalia arjuna is standardized to contain specific active metabolites effective in inhibiting PGT, thereby alleviating hypertension and cardiovascular complications.
In October, Sabinsa received a Mexican patent for a combination of ingredients touted for protecting hair.
The same month, it also scored three patents in Canada for its turmeric, ginger and peptide ingredients.
Last year, the company gained Non-GMO Project Verified status for eleven of its key ingredients.
Edited by Katherine Durrell
